Essential Thrombocythemia (ET) – MPN Research Foundation
Skip to content
MPN Research Foundation
Search for...
Menu
RESEARCH
Our Research Impact
MPN Challenge™
MPN Roundtable™
Patient-Focused Drug Development
2022 Thrive Initiative
MPN Interferon Initiative
Apply For Research Funding
PATIENTS & CAREGIVERS
MPN Clinical Trials
Patient & Caregiver Stories
Patient Bill of Rights
Find Support
UNDERSTANDING MPNS
Essential Thrombocythemia (ET)
Polycythemia Vera (PV)
Myelofibrosis (MF)
30 Facts about MPNs
Glossary
SUPPORT US
Make a Donation
Other Ways to Give
Create Your Own Fundraiser
ABOUT MPNRF
Our Mission & History
Board of Directors
Our Team
Scientific Advisory Board
News & Articles
Newsletters
Our Partners
DONATE
JOIN COMMUNITY
Essential Thrombocythemia (ET)
Essential Thrombocythemia (ET)
CPAP Treatment
by
MPNRF
March 11, 2021
Vactosertib
by
MPNRF
March 11, 2021
PRT543
by
MPNRF
March 11, 2021
CALR Exon 9 Mutant Peptide Vaccine
by
MPNRF
March 11, 2021
Givinostat
by
MPNRF
March 11, 2021
Ruxolitinib vs. Anagrelide
by
MPNRF
March 11, 2021
Ruxolitinib – Ruxo-BEAT trial
by
MPNRF
March 11, 2021
Ruxolitinib vs BAT
by
MPNRF
March 11, 2021
PU-H71
by
MPNRF
March 11, 2021
Familial Study of MPDs
by
MPNRF
March 11, 2021